Floatz logo

Aipalolitovorelizumab

Adjuvant Therapy

The First Affiliated Hospital with Nanjing Medical UniversityN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

27 Active assets in the Adjuvant Therapy cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Fujian Cancer Hospital
Phase 3B
Arimidex
Fujian Cancer Hospital
Phase 3B
Letrozole
Fujian Cancer Hospital
Phase 3B
EXEMESTANE
Fujian Cancer Hospital
Phase 3B
TRASTUZUMAB
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3B

View all 30 →

Same molecule, other indications

Aipalolitovorelizumab is also rated in:

colorectal cancerDormant
CC
Indicative ·
46 / 100
View asset →
triple-negative breast carcinomaDormant
D
Indicative ·
30 / 100
View asset →
metastatic malignant neoplasm in the lymph nodesDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →